ARDX
Ardelyx, Inc.
ARDX lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
ARDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARDX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
ARDX PE Valuation
ARDX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 253x next year's earnings.
ARDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ARDX to return to profit, with revenue growing. However, they disagree widely on these estimates.
ARDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | — |
| Q3 2026 | -$0.23 | +$0.01 |
| Q2 2026 | -$0.23 | +$0.01 |
| Q1 2026 | -$0.24 | -$0.01 |
| Q4 2025 | -$0.26 | -$0.09 |
| Q3 2025 | -$0.24 | +$0.06 |
| Q2 2025 | -$0.24 | +$0.03 |
| Q1 2025 | -$0.23 | +$0.05 |
| Q4 2024 | -$0.17 | +$0.13 |
ARDX is still losing money, but far less than before: $0.23 per share over the past year, against $1.13 at its worst in mid-2022.
ARDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.7M | +16% |
| Q2 2026 | $120.9M | +24% |
| Q1 2026 | $94.5M | +27% |
| Q4 2025 | $125.2M | +7.8% |
| Q3 2025 | $110.3M | +12% |
| Q2 2025 | $97.7M | +33% |
| Q1 2025 | $74.1M | +61% |
| Q4 2024 | $116.1M | +238% |
ARDX's revenue has grown year over year for 11 quarters in a row: $128M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.1% | -1.1 points |
| Q2 2026 | -10% | +4.5 points |
| Q1 2026 | -35% | +14 points |
| Q4 2025 | 4.1% | -2.9 points |
| Q3 2025 | 4.2% | +2 points |
| Q2 2025 | -15% | +3.9 points |
| Q1 2025 | -49% | +4.6 points |
| Q4 2024 | 7% | +88 points |
ARDX's operating margin was 3.1% last quarter, down 1.1 points from the same quarter a year ago.
ARDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +939% |
| Q2 2026 | -$6.4M | +$19.6M |
| Q1 2026 | -$32.3M | +$6.5M |
| Q4 2025 | $20.6M | +123% |
| Q3 2025 | $209K | -43% |
| Q2 2025 | -$26M | -$6.5M |
| Q1 2025 | -$38.8M | -$2.9M |
| Q4 2024 | $9.2M | +$18M |
ARDX has burned cash in most quarters: −$16M over the past year, against −$55M the year before.
ARDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.9M shares |
| 1 year | +3.3% | +8.1M shares |
| 3 years | +9.7% | +22.1M shares |
| 5 years | -30% | -108M shares |
ARDX has 250M diluted shares, up 3.3% from a year ago.
ARDX Net Leverage
ARDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ARDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 9.8 | Oversold |
ARDX's weekly RSI is 30 (neutral) and its Stochastic is 10 (oversold).
ARDX PE vs Healthcare Sector
ARDX has no meaningful PE right now: it lost money over the past year.
ARDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.15 | 1% below |
| 20 week MA | $3.88 | 20% below |
| 50 week MA | $5.32 | 41% below |
| 100 week MA | $5.17 | 40% below |
| 200 week MA | $5.30 | 41% below |
ARDX is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
ARDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.86 | $1.72 | -7.5% |
| 2021 | $1.72 | $1.18 | -31% |
| 2022 | $1.18 | $2.41 | +104% |
| 2023 | $2.41 | $6.20 | +157% |
| 2024 | $6.20 | $5.21 | -16% |
| 2025 | $5.21 | $5.74 | +10% |
| 2026 YTD | $5.74 | $3.12 | -46% |
ARDX has finished lower in three of the last six years. It's down 46% so far in 2026.